HALO

Halozyme Therapeutics Stock Analysis

AI Rating

Good
  • Quality9/10
  • Growth↑ 5/10
  • Value↓ 2/10
Halozyme Therapeutics sales and earnings growth
HALO Growth
Neutral
  • Revenue Y/Y↑ 37.55%
  • EPS Y/Y↓ -24.57%
  • FCF Y/Y↑ 37.62%
Halozyme Therapeutics gross and profit margin trends
HALO Profitability
Great
  • Gross margin ↑ 83.60%
  • EPS margin↑ 22.70%
  • ROIC 5Y↑ 21.17%
Halozyme Therapeutics net debt vs free cash flow
HALO Risk
Poor
  • Debt / Equity↑ 43.9
  • Debt / FCF↓ 3.1
  • Interest coverage↑ 26.8

Halozyme Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Poor risk rating.

↗ More Biotechnology stocks